InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

- Current share price for CHM : $0.003

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$0 FY2026 Annual Report, creditor update and Board changes 1 Oct 2026 10:16AM $0.003 $0.003 fallen by 0%
$0 Suspension from Quotation 1 Oct 2026 9:34AM $0.003 $0.003 fallen by 0%
$0 Application for quotation of securities - CHM 29 Sep 2026 4:50PM $0.005 $0.003 fallen by 40%
$0 Application for quotation of securities - CHM 22 Sep 2026 12:32PM $0.007 $0.003 fallen by 57.14%
$0 Application for quotation of securities - CHM 4 Sep 2026 12:22PM $0.011 $0.003 fallen by 72.73%
$0 Appendix 4E and Preliminary Final Report 31 Aug 2026 5:36PM $0.011 $0.003 fallen by 72.73%
$0 Application for quotation of securities - CHM 27 Aug 2026 5:03PM $0.010 $0.003 fallen by 70%
$0 Application for quotation of securities - CHM 21 Aug 2026 12:45PM $0.020 $0.003 fallen by 84.62%
$0 CHM ceases enrolment in Phase 1 trial and Company update 19 Aug 2026 9:08AM $0.035 $0.003 fallen by 91.43%
$0 Trading Halt 17 Aug 2026 9:53AM $0.035 $0.003 fallen by 91.43%
$0 Application for quotation of securities - CHM 7 Aug 2026 12:04PM $0.041 $0.003 fallen by 92.68%
$0 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2026 3:03PM $0.043 $0.003 fallen by 93.02%
$0 Chimeric receives $1.62M advance on FY26 R&D tax incentive 29 Jul 2026 2:10PM $0.043 $0.003 fallen by 93.02%
$0 Investor Presentation 28 Jul 2026 11:19AM $0.036 $0.003 fallen by 91.67%
$0 Application for quotation of securities - CHM 22 Jul 2026 4:50PM $0.042 $0.003 fallen by 92.86%
$0 Notification regarding unquoted securities - CHM 17 Jul 2026 5:26PM $0.044 $0.003 fallen by 93.18%
$0 Notification regarding unquoted securities - CHM 17 Jul 2026 5:25PM $0.044 $0.003 fallen by 93.18%
$0 CHM CDH17 Phase 1 clinical trial update - New DL 3 data 16 Jul 2026 9:04AM $0.051 $0.003 fallen by 94.12%
$0 Application for quotation of securities - CHM 14 Jul 2026 5:11PM $0.053 $0.003 fallen by 94.34%
$0 Notification of cessation of securities - CHM 14 Jul 2026 4:28PM $0.053 $0.003 fallen by 94.34%
$0 Final Director's Interest Notice 7 Jul 2026 2:41PM $0.063 $0.003 fallen by 95.24%
$0 Board Update 6 Jul 2026 9:01AM $0.058 $0.003 fallen by 94.83%
$0 Application for quotation of securities - CHM 2 Jul 2026 4:24PM $0.059 $0.003 fallen by 94.92%
$0 Appointment of Financial Adviser for Strategic Review 1 Jul 2026 9:01AM $0.065 $0.003 fallen by 95.38%
$0 Application for quotation of securities - CHM 11 Jun 2026 5:08PM $0.076 $0.003 fallen by 96.05%

1 - 25 of 650 results

Page 1 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.